Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

Latest news

More from news
Approximately 42 fully matching, plus 143 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies.

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    We won’t compete directly with big vaccine companies, but may partner with them to support late phase product development and commercialisation. ... This is hard to know. The value of T cell approaches, especially CD8 T cells, has been shown by the

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

More from intelligence
Approximately 0 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The impossible launch

    SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.

  • Launch Excellence 2020

    How can you use insights to understand customers decision-making behaviour? What are you missing in your CAR-T service launch?

  • Understanding the evolving CAR-T market

    The CAR-T was their last chance and only hope. Astoundingly, 83% achieved overall remission within just three months of treatment. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.

  • Precision medicine from concept to clinic

    What it’s like to treating paediatric patients with CAR-T at Great Ormond Street Children’s hospital.

More from PMHub
Approximately 4 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Novel endpoints
Novel endpoints in the digital age
Redesigning the goalposts...
Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Infographics